|Day Low/High||3.65 / 3.83|
|52 Wk Low/High||3.18 / 10.98|
Preclinical data from Chk1 inhibitor program and first presentation characterizing lead TIGIT antibody
Cascadian's tucatinib delays regrowth of breast cancer by a median of 7.8 months in newly updated study results presented this week.
Poster session at ESMO 2016 Congress reviews evidence of clinical activity in patients with skin metastases
Special meeting to be held November 18, 2016 to seek stockholder approval
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.